Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030050/S054

SCULPTRA AND SCULPTRA AESTHETIC

Q-Med AB · Decision date Apr 15, 2026

FDA DECISIONP030050/S054

What did the FDA approve?

FDA records P030050/S054 as a supplement to PMA P030050, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 15, 2026.

FDA approval order statement

Approval to terminate elemental impurity testing for Sculptra vial stoppers
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
General, Plastic Surgery
Decision date
Apr 15, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P030050/S054
Regulatory pathway
PMA supplement
Applicant
Q-Med AB
Product code
LMH
Decision code
APPR
Decision date
Apr 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Q-Med AB
Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P030050. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030050 · Original PMA

    SCULPTRA AND SCULPTRA AESTHETIC

  2. P030050/S054 received

    Application receipt date recorded by FDA.

  3. P030050/S054 · FDA decision

    Real-Time Process

  4. P030050/S055 · Related supplement

    SCULPTRA (injectable poly-L Lactic acid)

  5. P030050/S056 · Related supplement

    SCULPTRA (injectable poly-L Lactic acid)

Timeline entries are records held by MedtechLedger for P030050. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030050

Product / regulatory recordCompanyPathwayDecision dateSource
Q-Med ABPMA approvalAug 3, 2004FDA
Q-Med ABPMA supplementJun 22, 2026FDA
Q-Med ABPMA supplementSep 17, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Q-Med AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seminariegatan 21, Uppsala, SE-752-28

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records